Zydus Lifesciences share pros and cons: India pharma value at cheap 22x PE analysed for 2026. Saroglitazar novel drug innovation, US complex generics, consumer wellness brands, and growth scale challenges covered.

Ipca Laboratories share pros and cons: anti-malarial API global leader in FDA recovery mode analysed for 2026. API market leadership, balanced revenue model, regulatory history, and US re-entry optionality covered.

Natco Pharma share pros and cons: India’s cheapest pharma at 12x PE with Para-IV oncology strategy analysed for 2026. Patent challenge model, exclusivity earnings, lumpy revenue risks, and cheap valuation opportunity covered.

Coal India share pros and cons: world’s largest coal producer at cheap 8x PE and 6.5 percent yield. India energy security role, energy transition risk, and PSU governance constraints covered.

Torrent Power share pros and cons: India’s best private integrated utility analysed for 2026. Ahmedabad distribution, Torrent governance, renewable expansion, PE premium, and debt risks covered.

JSW Energy share pros and cons: JSW Group’s renewable energy pivot with 20 GW green target analysed for 2026. Institutional backing, ambitious renewable pipeline, high debt, and elevated PE risks covered.

Data Patterns share pros and cons: genuine defence electronics mid-cap at very high 93x PE analysed for 2026. Astra missile involvement, DRDO programme depth, revenue lumpiness, and small-cap concentration risks covered.

Blue Star share pros and cons: India’s commercial AC specialist analysed for 2026. Institutional client leadership, data centre cooling, Voltas competition, project cyclicality risks, and 64x PE covered.

Check the Nifty Consumer Durables prediction for tomorrow for Friday 7 August 2026. Nifty Consumer Durables at 40,320 (+0.17%). SBI Q1 FY27 board Aug 7. Brent $